12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Brilacidin: Phase IIb start

Early next year, PolyMedix said it plans to begin a dose-optimization Phase IIb trial of single dose and 3-day dosing regimens of brilacidin. At a Type B pre-NDA meeting with FDA, PolyMedix said the agency supported the proposed regimens...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >